NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 04:00PM ET
1.76
Dollar change
+0.03
Percentage change
1.73
%
Index- P/E- EPS (ttm)- Insider Own60.36% Shs Outstand9.44M Perf Week4.14%
Market Cap16.61M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.74M Perf Month10.00%
Enterprise Value17.13M PEG- EPS next Q- Inst Own1.11% Short Float3.37% Perf Quarter69.23%
Income- P/S- EPS this Y- Inst Trans4.63% Short Ratio0.04 Perf Half Y-28.46%
Sales- P/B1.46 EPS next Y- ROA- Short Interest0.13M Perf YTD-24.14%
Book/sh1.21 P/C8.79 EPS next 5Y- ROE- 52W High5.50 -68.00% Perf Year-
Cash/sh0.20 P/FCF- EPS past 3/5Y2.48% - ROIC- 52W Low0.77 128.54% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility13.14% 16.06% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)0.28 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.08 Sales Y/Y TTM- Profit Margin- RSI (14)48.65 Recom-
Dividend Gr. 3/5Y- - Current Ratio0.79 EPS Q/Q- SMA20-6.88% Beta- Target Price-
Payout- Debt/Eq0.21 Sales Q/Q- SMA50-3.75% Rel Volume0.01 Prev Close1.73
Employees20 LT Debt/Eq0.00 Earnings- SMA200-9.03% Avg Volume2.82M Price1.76
IPOOct 29, 2024 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume19,955 Change1.73%
Jun-10-25 07:30AM
May-03-25 11:00AM
Feb-27-25 08:45AM
Feb-04-25 08:00AM
Jan-24-25 08:00AM
08:30AM Loading…
Dec-19-24 08:30AM
Dec-17-24 08:30AM
Dec-09-24 08:30AM
Dec-02-24 08:30AM
Nov-26-24 08:30AM
Nov-12-24 09:00AM
Oct-30-24 10:00AM
Oct-28-24 09:50PM
Gelteq Ltd. is a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.